Petros Pharmaceuticals, Inc. — Revenue by Fiscal Year
5 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/cd0bf364-5602-40c1-a6aa-fbac8b133cda/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2024 | $5.1M | 2024-01-01 – 2024-12-31 | evidence 0001410578-25-000579 |
| FY 2023 | $5.8M | 2023-01-01 – 2023-12-31 | evidence 0001410578-24-000401 |
| FY 2022 | $6.0M | 2022-01-01 – 2022-12-31 | evidence 0001410578-23-000575 |
| FY 2021 | $7.8M | 2021-01-01 – 2021-12-31 | evidence 0001410578-22-000783 |
| FY 2020 | $9.6M | 2020-01-01 – 2020-12-31 | evidence 0001410578-22-000783 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Petros Pharmaceuticals, Inc. — all facts · Net Income · Operating Income